Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE Antitumor Effects of Blocking Protein Neddylation in T315I-BCR-ABL Leukemia Cells and Leukemia Stem Cells. 29321163

2018

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE Collectively, the present results suggest that in the treatment of leukemia, taxodione has potential as a compound with high efficacy to overcome BCR-ABL T315I mutation-mediated resistance in leukemia cells. 29859988

2018

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE T315I mutation of BCR-ABL1 into human Philadelphia chromosome-positive leukemia cell lines by homologous recombination using the CRISPR/Cas9 system. 29967475

2018

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE Ponatinib-Induced Graft-versus-Host Disease/Graft-versus-Leukemia Effect in a Patient with Philadelphia-Positive Acute Lymphoblastic Leukemia without the T315I Mutation Relapsing after Allogeneic Transplant. 28810255

2017

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE Surprisingly, inhibition of AurA by AKI603 induced leukemia cell senescence in both BCR-ABL wild type and T315I mutation cells. 27824120

2016

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE In BCR/ABL- or BCR/ABL-T315I-driven murine leukemia as well as in xenograft models of primary Ph+ leukemia harboring the T315I, PF-114 significantly prolonged survival to a similar extent as ponatinib. 25394714

2015

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE Ponatinib is the only currently approved tyrosine kinase inhibitor (TKI) that suppresses all BCR-ABL1 single mutants in Philadelphia chromosome-positive (Ph(+)) leukemia, including the recalcitrant BCR-ABL1(T315I) mutant. 25132497

2014

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE MK-0457, an Aurora kinase and BCR-ABL inhibitor, is active in patients with BCR-ABL T315I leukemia. 22772060

2013

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE One mutation, T315I, for example, renders the leukemia resistant to all first- and second-line TKIs. 23666688

2013

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE Given the fact that all AKIs fail to inhibit BCR/ABL harboring the 'gatekeeper' mutation T315I, we investigated the effects of AKIs in combination with the allosteric inhibitor GNF2 in Ph + leukemia. 22985168

2012

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE Although strategies to overcome resistance-mediated T315I mutation may improve the survival of BCR-ABL-positive leukemia patients, there is little information on cell-based studies. 20471447

2010

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE Although many imatinib-resistant mutations respond well to second-generation TKIs, the threonine-to-isoleucine mutation at codon 315 of the breakpoint cluster region/v-abl Abelson murine leukemia viral oncogene protein fusion Bcr-Abl (T315I) is insensitive to all currently available TKIs. 20564073

2010

dbSNP: rs121913459
rs121913459
0.100 GeneticVariation BEFREE KW-2449, a multikinase inhibitor of FLT3, ABL, ABL-T315I, and Aurora kinase, is under investigation to treat leukemia patients. 19541823

2009

dbSNP: rs77375493
rs77375493
0.060 GeneticVariation BEFREE Here we show that retroviral overexpression of Jak2 V617F mutant into wild-type p53 murine bone marrow cells induced polycythemia vera (PV) in the recipient mice, whereas Jak2 V617F-transduced p53-null mice developed lethal leukemia after the preceding PV phase. 28068330

2017

dbSNP: rs1217691063
rs1217691063
0.060 GeneticVariation BEFREE We investigated the risks of adult leukemia with genetic polymorphisms of folate metabolic enzymes (MTHFR C677T, A1298C, and TS) and evaluated if the associations varied by dietary folate intake from a multicenter case-control study conducted in Chinese. 26438060

2016

dbSNP: rs77375493
rs77375493
0.060 GeneticVariation BEFREE Mutations in the thrombopoietin receptor gene (myeloproliferative leukemia, MPL) have been reported in patients with JAK2 V617F-negative chronic myeloproliferative disorders (MPDs). 21326037

2011

dbSNP: rs77375493
rs77375493
0.060 GeneticVariation BEFREE Among the patients with myelofibrosis, those with ASXL1 lesions were not distinguished from their wild-type counterparts with regard to JAK2 V617F status, exposure to chemotherapy or evolution to leukemia. 21712540

2011

dbSNP: rs1217691063
rs1217691063
0.060 GeneticVariation BEFREE Recipient MTHFR polymorphisms (C677T) were associated with acute GvHD (P=0.03), and recipient VDR TaqI with TRM and overall survival (P=0.006 and P=0.04, respectively).Genetic factors that interfere with drug metabolisms are associated with treatment-related toxicities, GvHD and survival after HLA-identical HSCT in patients with leukemia and should be investigated prospectively. 19005482

2009

dbSNP: rs77375493
rs77375493
0.060 GeneticVariation BEFREE JAK2 (V617F)-positive ET may evolve in few instances into JAK2-negative leukemia. 19691103

2009

dbSNP: rs1217691063
rs1217691063
0.060 GeneticVariation BEFREE Methylenetetrahydrofolate reductase (MTHFR) C677T and thymidylate synthase promoter (TSER) polymorphisms in Indonesian children with and without leukemia. 17395259

2008

dbSNP: rs77375493
rs77375493
0.060 GeneticVariation BEFREE The incidence of JAK2 V617F in patients with a core binding factor (CBF) leukemia was 3.6% (p<0.01). 17229652

2007

dbSNP: rs77375493
rs77375493
0.060 GeneticVariation BEFREE Homozygous V617F mutation is associated with the clinical picture of classic PV and with a higher tendency to secondary myelofibrosis, but with no increased leukemia unless other biological or genetic factors come into play, such as myelosuppressive agents or the acquisition of additional biologic or genetic defects. 16810614

2006

dbSNP: rs1217691063
rs1217691063
0.060 GeneticVariation BEFREE The role of methylenetetrahydrofolate reductase (MTHFR C677T), glutathione S-transferases (GSTM1 and GSTT1 null, GSTP1 Ile105Val), and cytochromes p450 (CYP1A1*2A) genotypes in the etiology of childhood leukemia was simultaneously investigated. 12827651

2003

dbSNP: rs1217691063
rs1217691063
0.060 GeneticVariation BEFREE In this study we describe the genotyping of the MTHFR C677T polymorphism by melting curve analysis with the LightCycler in a case-controlled study of patients with acute lymphocytic leukemia (ALL), myelogenous leukemia (AML), and chronic myelogenous leukemia (CML), and assess the effect of this common polymorphism on the leukemia risk in adult patients in Turkey. 15068389

2003

dbSNP: rs1217691063
rs1217691063
0.060 GeneticVariation BEFREE Preponderance of methylenetetrahydrofolate reductase C677T homozygosity among leukemia patients intolerant to methotrexate. 12453860

2002